MARKET

NHWK

NHWK

NightHawk
AMEX

Real-time Quotes | Nasdaq Last Sale

2.450
+0.240
+10.86%
After Hours: 2.460 +0.01 +0.41% 19:59 05/17 EDT
OPEN
2.250
PREV CLOSE
2.210
HIGH
2.460
LOW
2.170
VOLUME
109.30K
TURNOVER
0
52 WEEK HIGH
10.85
52 WEEK LOW
1.600
MARKET CAP
62.84M
P/E (TTM)
-1.7424
1D
5D
1M
3M
1Y
5Y
NightHawk Biosciences GAAP EPS of -$0.32 beats by $0.17
NightHawk Biosciences press release (NYSE:NHWK): Q1 GAAP EPS of -$0.32 beats by $0.17. Recognized $0.2 million of grant revenue for qualified expenditures under the CPRIT grant for the quarter ended
Seekingalpha · 1d ago
NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D...
GlobeNewswire · 05/10 12:00
Morrisville drugmaker scores $6M deal with Canada for anthrax treatment
The Canadian contract follows a recent deal with the U.S. government worth up to $81 million for the anthrax treatment.
American City Business Journals · 04/27 19:15
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by NightHawkDURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully int...
GlobeNewswire · 04/27 12:00
Morrisville drugmaker changing name, subsidiary plans $650M manufacturing facility in Kansas
A public company headquartered in Morrisville is preparing to change its name as one of its subsidiaries plans a 500-job manufacturing facility for biodefense in Kansas.
American City Business Journals · 04/21 12:01
Heat Biologics to rebrand as NightHawk Biosciences from next month
The clinical-stage biotech, Heat Biologics (NYSE:HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03. The name change will coincide with a change in
Seekingalpha · 04/19 15:49
Heat Biologics Announces Planned Name Change To NightHawk Biosciences; Will Trade Under Ticker 'NHWK' Effective May 3, 2022
Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune
Benzinga · 04/19 15:01
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.comDURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical co...
GlobeNewswire · 04/19 15:00
More
No Data
Learn about the latest financial forecast of NHWK. Analyze the recent business situations of NightHawk through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NHWK stock price target is 11.38 with a high estimate of 15.50 and a low estimate of 8.00.
High15.50
Average11.38
Low8.00
Current 2.450
EPS
Actual
Estimate
-0.43-0.32-0.22-0.11
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 2.83M
% Owned: 11.04%
Shares Outstanding: 25.65M
TypeInstitutionsShares
Increased
15
202.34K
New
3
63.36K
Decreased
7
18.00K
Sold Out
5
72.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.06%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Wolf
Chief Financial Officer/Controller/Secretary
William Ostrander
Lead Director/Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith
No Data
No Data
About NHWK
Heat Biologics, Inc. is a biopharmaceutical company primarily engaged in the development of immune therapies and vaccines. Its gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. HS-110 (viagenpumatucel-L) is its allogeneic cell line biologic product candidate in a series of immunotherapies designed to stimulate a patient’s T-cells to destroy cancer utilizing its gp96 platform. HS-130 is an allogeneic cell line engineered to express the extracellular domain of OX40 ligand fusion protein (OX40L-Fc), a costimulator of T-cells, with the potential to augment antigen-specific CD4+ T-cell and CD8+ T-cell responses when combined with its gp96 platform. It has also developed a COVID-19 vaccine program under its Zolovax, Inc. subsidiary that utilizes its gp96 platform to secrete SARS-CoV-2 antigens.

Webull offers kinds of Heat Biologics Inc stock information, including AMEX:NHWK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NHWK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NHWK stock methods without spending real money on the virtual paper trading platform.